Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
Stefano IndraccoloGian Luca De SalvoMartina VerzaMario CacceseGiovanni EspositoIlaria PigaPaola Del BiancoMarco PizziMarina Paola GardimanMarica EoliRoberta RudàAlba Ariela BrandesToni IbrahimSimona RizzatoIvan LolliVittorina ZagonelGiuseppe LombardiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We found that AMPK pathway activation is associated with clinical benefit from treatment with regorafenib in relapsed GBM.